All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Pfizer Inc. and Clear Creek Bio Inc. have entered into a research collaboration and exclusive license agreement to advance the discovery and development of potential inhibitors of the SARS-CoV-2 papain-like protease (PLpro) for the oral treatment of COVID-19.
Blue Water Vaccines Inc. has signed an exclusive, global license agreement for the development of a live attenuated, oral chlamydia vaccine candidate from The University of Texas (UT) Health San Antonio. Developed at UT Health San Antonio, the novel vaccine candidate utilizes a live attenuated chlamydia strain, Chlamydia muridarum.
Collplant Biotechnologies Ltd. and Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University and Sheba Medical Center, have entered into a license and research agreement to codevelop a gut-on-a-chip tissue model for drug discovery and high-throughput screening of drugs.
Biotheus Inc. has entered into a license and collaboration agreement with Hansoh Pharmaceuticals (Hansoh Pharmaceutical Group Co. Ltd.) for Biotheus' EGFR/MET bispecific antibody PM-1080 in Greater China, including mainland China, Hong Kong, Macao and Taiwan.
MGFB, a subsidiary of Fairwinds Bio, has entered into a patent license agreement with Mayo Clinic to advance experimental cancer vaccine therapeutics based on a novel platform developed at Mayo.
Cabaletta Bio Inc. has announced CABA-201, a newly designed, fully human CD19 chimeric antigen receptor (CAR) containing a 4-1BB co-stimulatory domain.
RSS
